Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ICML 2019

Hodgkin Lymphoma

View all
1:46
Road ahead for immunotherapy in Hodgkin lymphoma: bispecifics & CAR-T
Stephen Ansell • 19 Jun 2019
2:01
Immune targeting of the microenvironment in classical Hodgkin lymphoma
Catherine Diefenbach • 19 Jun 2019

non-Hodgkin Lymphoma

View all
2:37
MabCute results: extended subcutaneous R maintenance for indolent NHL
Simon Rule • 19 Jun 2019
0:53
CAR-T horizons in NHL
Anna Sureda • 19 Jun 2019

CLL

View all
1:42
Moving towards chemo-free regimens in CLL
Michael Hallek • 19 Jun 2019
1:11
Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
Kerry Rogers • 19 Jun 2019

DLBCL

View all
2:59
Axi-cel in older patients: data from ZUMA-1 and clinical use
Sattva Neelapu • 19 Jun 2019
3:50
Updates in the management of CAR-T toxicities
Sattva Neelapu • 19 Jun 2019

MCL

View all
1:07
MCL trials to watch out for at ASH 2019
Simon Rule • 19 Jun 2019
0:55
Zanubrutinib in mantle cell lymphoma: updated safety and efficacy data
Constantine Tam • 20 Jun 2019

FL

View all
2:37
MabCute results: extended subcutaneous R maintenance for indolent NHL
Simon Rule • 19 Jun 2019
1:48
Zanubrutinib plus obinutuzumab: CLL, SLL & FL
Constantine Tam • 20 Jun 2019

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals